AAD Issues Guidelines for Treatment of Nonmelanoma Skin Cancer
Skin cancer is the most common cancer in the United States, and nonmelanoma skin cancer is the most common type of skin cancer, affecting more than 3 million Americans every year. Moreover, nonmelanoma skin cancer incidence is growing at an exponential rate—between 1976–1984 and 2000–2010, the overall incidence of basal cell carcinoma increased by 145%, and the overall incidence of squamous cell carcinoma increased by 263%.
The American Academy of Dermatology (AAD) has addressed this growing health concern with the release of its guidelines of care for the management of basal cell carcinoma and cutaneous squamous cell carcinoma, published in the Journal of the American Academy of Dermatology. Developed by a work group composed of board-certified dermatologists and other experts in the field, the evidence-based guidelines cover best practices for the management of nonmelanoma skin cancer.
“These two guidelines will help doctors provide the best possible care for patients with basal cell carcinoma and squamous cell carcinoma,” said board-certified dermatologist Christopher K. Bichakjian, MD, FAAD, Co-Chair of the work group that developed the guidelines. “If they are left untreated, some nonmelanoma skin cancers may grow and spread, potentially leading to disfigurement and even death. When detected early, however, these skin cancers are highly treatable.”
Treatment Recommendations
According to the guidelines, surgical treatment—excision, Mohs surgery, or curettage and electrodessication—is the most effective option for most cases of nonmelanoma skin cancer. In some cases, however, doctors may consider other treatments, such as cryotherapy, radiation, or topical therapy. The guidelines do not include recommendations for treating nonmelanoma skin cancer with laser therapy or electronic brachytherapy, as there was not enough evidence available for the work group to make an informed decision.
“Board-certified dermatologists have the training, knowledge, and experience to provide nonmelanoma skin cancer patients with the highest-quality care,” says board-certified dermatologist Murad Alam, MD, FAAD, Co-Chair of the guidelines work group. “If you are diagnosed with basal cell carcinoma or squamous cell carcinoma, a board-certified dermatologist can work with you to determine the treatment option that’s best for you.”
To emphasize the importance of considering the patient perspective in determining how to treat basal cell carcinoma and squamous cell carcinoma, the AAD’s work group included patient advocate Kristi Schmitt Burr, who has been dealing with nonmelanoma skin cancers for more than 5 decades due to a genetic condition called basal cell nevus syndrome (also known as Gorlin-Goltz syndrome). Ms. Burr explained that it’s important for patients to understand their available treatment options and to have input in their medical care.
“I sincerely appreciate the AAD’s including patient engagement as an integral component in developing these guidelines, as it is vital for patients and their families to have a voice in their care,” Ms. Burr said. “Over the decades, trained dermatologists have provided my family with ample resources and counseling to help us achieve optimal outcomes. I hope these guidelines encourage further dialogs between expert doctors, their skilled staff, and the patients in their care.”
Follow-up Guidelines
In addition to providing recommendations on nonmelanoma skin cancer treatment, the guidelines also provide follow-up recommendations for patients who have been diagnosed with basal cell carcinoma or squamous cell carcinoma. According to the guidelines, these patients should receive an exam to check for new skin cancers at least once a year and take steps to prevent the development of future skin cancers. The AAD recommends that everyone, whether or not they have had a previous skin cancer, protect themselves from the sun’s harmful ultraviolet rays by seeking shade, wearing protective clothing, and using a broad-spectrum, water-resistant sunscreen with a sun protection factor of 30 or higher.
The AAD also recommends that everyone perform regular skin self-exams to detect skin cancer early, when it’s most treatable. Those who notice any new or suspicious spots on their skin, as well as anything changing, itching, or bleeding, should see a board-certified dermatologist.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
